Straits Times Index
3,129.48 -8.06 (-0.26%) Nikkei
26,830.69 -40.58 (-0.15%) Hang Seng
22,018.47 -211.05 (-0.95%) FTSE 100
7,258.32 +49.51 (+0.69%) BTC-USD
20,630.42 -498.98 (-2.36%) CMC Crypto 200
448.14 -13.65 (-2.96%)
Repare Therapeutics Inc. (RPTX)
After hours:
| Previous close | 14.84 |
| Open | 14.77 |
| Bid | 14.00 x 1200 |
| Ask | 14.77 x 1000 |
| Day's range | 14.29 - 15.10 |
| 52-week range | 8.06 - 35.75 |
| Volume | |
| Avg. volume | 871,729 |
| Market cap | 618.777M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
CAMBRIDGE, Mass. & MONTREAL, June 07, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA.
- Business Wire
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
CAMBRIDGE, Mass. & MONTREAL, June 01, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific
- Business Wire
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
CAMBRIDGE, Mass. & MONTREAL, May 09, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
